Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CHM 2101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CHM 2101 is a 3rd generation, novel CDH17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including colorectal cancer, gastric cancer and neuroendocrine tumor...
Product Name : CHM 2101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : CHM 2101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial
Details : CHM 1101 (Chlorotoxin CAR T Cell Therapy) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma.
Product Name : CHM 1101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 06, 2023
Chimeric Enters Strategic Manufacturing Partnership With WuXi Advanced Therapies
Details : The partnership initially focusses on Chimeric’s two autologous CAR T-cell therapies for solid tumours: CHM 2101, currently in late preclinical for gastrointestinal cancers and CHM 1101 (CLTX CAR T), currently in single-site phase 1 for recurrent or pr...
Product Name : CHM 1101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 04, 2022
Reset All
